Needham & Company LLC Lowers Merit Medical Systems (NASDAQ:MMSI) Price Target to $101.00

Merit Medical Systems (NASDAQ:MMSI) had its price target lowered by Needham & Company LLC from $108.00 to $101.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the medical instruments supplier’s stock. Needham & Company LLC’s price target suggests a potential upside of 29.45% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Robert W. Baird set a $108.00 price target on Merit Medical Systems in a research report on Tuesday, December 16th. BTIG Research started coverage on Merit Medical Systems in a research report on Friday, February 6th. They set a “buy” rating and a $107.00 target price on the stock. Wells Fargo & Company lowered their price target on Merit Medical Systems from $103.00 to $95.00 and set an “overweight” rating for the company in a report on Friday, November 14th. Zacks Research lowered Merit Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Merit Medical Systems in a research report on Monday, December 29th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $103.33.

Merit Medical Systems Trading Down 1.5%

MMSI opened at $78.02 on Wednesday. The company has a current ratio of 4.34, a quick ratio of 2.86 and a debt-to-equity ratio of 0.46. The firm has a market cap of $4.64 billion, a price-to-earnings ratio of 36.80, a PEG ratio of 2.15 and a beta of 0.61. Merit Medical Systems has a 12 month low of $76.68 and a 12 month high of $107.27. The stock has a fifty day moving average price of $83.73 and a 200-day moving average price of $84.89.

Merit Medical Systems (NASDAQ:MMSI) last posted its earnings results on Tuesday, February 24th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.08. The company had revenue of $393.94 million for the quarter, compared to analyst estimates of $390.77 million. Merit Medical Systems had a return on equity of 13.82% and a net margin of 8.48%.The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.93 earnings per share. Merit Medical Systems has set its FY 2026 guidance at 4.010-4.150 EPS. As a group, equities research analysts anticipate that Merit Medical Systems will post 3.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Merit Medical Systems

Institutional investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL purchased a new stake in shares of Merit Medical Systems in the third quarter worth about $2,913,050,000. State Street Corp boosted its position in Merit Medical Systems by 1.5% in the 4th quarter. State Street Corp now owns 2,231,048 shares of the medical instruments supplier’s stock worth $196,645,000 after purchasing an additional 32,459 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its position in Merit Medical Systems by 12.7% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,077,796 shares of the medical instruments supplier’s stock worth $183,137,000 after purchasing an additional 234,682 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Merit Medical Systems by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,437,397 shares of the medical instruments supplier’s stock worth $134,384,000 after purchasing an additional 39,620 shares during the period. Finally, Maverick Capital Ltd. increased its holdings in shares of Merit Medical Systems by 8.4% during the 2nd quarter. Maverick Capital Ltd. now owns 1,379,408 shares of the medical instruments supplier’s stock valued at $128,947,000 after purchasing an additional 106,897 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Key Headlines Impacting Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 results beat expectations: EPS and revenue topped consensus, margins expanded driven by Cardiovascular strength and solid U.S. & EMEA sales — a fundamental driver supporting the stock. Merit Medical Q4 Earnings & Revenues Beat Estimate, Margins Expand
• Positive Sentiment: Barrington Research raised its price target to $109 and maintained an “outperform” rating, signaling bullish analyst conviction that the company can deliver upside from current levels. Barrington Research raises PT to $109
• Positive Sentiment: Management projects 6%–8% revenue growth for 2026 and is divesting the DualCap business to focus on strengthening global platforms—this strategic clarity and growth guide support medium‑term revenue expansion. Merit projects 6%-8% revenue growth for 2026 while divesting
• Neutral Sentiment: Earnings call presentation and detailed slides are available for review — useful for investors digging into segment performance and margin drivers but not new market-moving information on their own. Q4 results presentation
• Neutral Sentiment: Analyst notes and metric comparisons provide context on how the quarter stacks vs. estimates and prior-year numbers—helpful for modeling but not immediately directional. Zacks: Q4 key metrics vs estimates
• Neutral Sentiment: General earnings highlights and recap pieces summarize the beat and guidance for investors who want a quick read. Yahoo Finance earnings highlights
• Neutral Sentiment: Needham kept a Buy rating, citing the strong quarter and outlook, but trimmed its price target to $101 — a mixed signal (positive conviction on fundamentals, smaller near-term upside in the analyst view). TipRanks: Needham maintains Buy, lowers PT
• Negative Sentiment: Wells Fargo downgraded MMSI from Overweight to Equal Weight and cut its price target to $78, signaling reduced near-term conviction and adding selling pressure. Wells Fargo downgrades to Equal Weight

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.